NCT00603512 - Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Placebo

0 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

10 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

1 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

3 mg BID, 3 blinded tablets administered BID for 12 weeks

DRUG

CP-690,550

5 mg BID, 3 blinded tablets administered BID for 12 weeks

Trial Locations (18)

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Hitachi-shi

Pfizer Investigational Site, Sagamihara

Pfizer Investigational Site, Yahatanishi-ku

Pfizer Investigational Site, Koushi

Pfizer Investigational Site, Sendai

Pfizer Investigational Site, Niigata

Pfizer Investigational Site, Kawachi-Nagano

Pfizer Investigational Site, Kawagoe-shi

Pfizer Investigational Site, Kitamoto

Pfizer Investigational Site, Bunkyo-ku

Pfizer Investigational Site, Bunkyo-k

Pfizer Investigational Site, Chiyoda-ku

Pfizer Investigational Site, Koto-ku

Pfizer Investigational Site, Meguro-ku

Pfizer Investigational Site, Musashimurayama-shi

Pfizer Investigational Site, Shinjyuku-ku